Cargando…
Development of highly stable and de-immunized versions of recombinant alpha interferon: Promising candidates for the treatment of chronic and emerging viral diseases
Human interferon alpha (hIFN-α) administration constitutes the current FDA approved therapy for chronic Hepatitis B and C virus infections. Additionally, hIFN-α treatment efficacy was recently demonstrated in patients with COVID-19. Thus, hIFN-α constitutes a therapeutic alternative for those countr...
Autores principales: | Giorgetti, Sofía Inés, Etcheverrigaray, Marina, Terry, Frances, Martin, William, De Groot, Anne Searls, Ceaglio, Natalia, Oggero, Marcos, Mufarrege, Eduardo Federico |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595249/ https://www.ncbi.nlm.nih.gov/pubmed/34798238 http://dx.doi.org/10.1016/j.clim.2021.108888 |
Ejemplares similares
-
Differences in the production of hyperglycosylated IFN alpha in CHO and HEK 293 cells
por: Gugliotta, Agustina, et al.
Publicado: (2013) -
Neuroprotective activity of a new erythropoietin formulation with increased penetration in the central nervous system
por: Etcheverrigaray, Marina, et al.
Publicado: (2011) -
New reporter cell clones to determine the biological activity of human type I interferons
por: Bürgi, Milagros, et al.
Publicado: (2011) -
Intraventricular recombinant alpha-interferon in subacute sclerosing panencephalitis
por: Cianchetti, C., et al.
Publicado: (1991) -
EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group.
por: De Mulder, P. H., et al.
Publicado: (1995)